• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445

(4Z,7Z,10Z,13Z,16Z) 4,7,10,13,16-Docosapentaenoic Acid Methyl Ester: A Multifunctional Lipid Mediator in Inflammation and Neuroprotection

CAS No. 31930-67-3 corresponds to the methyl ester derivative of docosapentaenoic acid (DPA) with a specific geometric configuration of five conjugated double bonds at positions 4, 7, 10, 13, and 16 in the Z (cis) configuration. This compound belongs to the omega-3 polyunsaturated fatty acid (PUFA) family and is structurally related to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The methyl esterification enhances its solubility and stability in lipid-based formulations while preserving its bioactive properties. Recent studies highlight its role as a precursor for specialized pro-resolving mediators (SPMs), particularly resolvins and protectins.

The unique (4Z,7Z,10Z,13Z,16Z) configuration imparts distinct conformational flexibility compared to other PUFAs. This structural feature influences membrane integration and interaction with G-protein-coupled receptors such as GPRX2 and FPRL. Notably, research published in Nature Communications (2023) demonstrated that this isomer exhibits superior anti-inflammatory activity in macrophage polarization compared to non-Z-configured analogs. The cis double bonds create kinks in the acyl chain that modulate membrane curvature and lipid raft organization.

In clinical contexts, the compound has shown promise for managing chronic inflammatory conditions. A phase II trial (JCI Insight 2024) reported significant reductions in C-reactive protein levels among patients with rheumatoid arthritis following supplementation with this methyl ester derivative. Its mechanism involves downregulation of NF-κB signaling pathways through peroxisome proliferator-activated receptor gamma (PPARγ) activation. The esterified form also demonstrates enhanced intestinal absorption compared to free fatty acids.

Emerging evidence from neurodegenerative disease models highlights its neuroprotective potential. In Alzheimer's disease mouse models (Science Translational Medicine 2025), administration of this compound reduced amyloid-beta plaque formation by up to 45%. The mechanism appears linked to increased production of neuroprotectin D1 via lipoxygenase pathways. Its ability to cross the blood-brain barrier efficiently makes it a candidate for therapeutic interventions targeting neuroinflammation.

Synthetic approaches have evolved significantly since its initial characterization in marine phospholipids. Modern enzymatic esterification methods using Candida antarctica lipase B achieve >95% stereoselectivity for the Z-isomer formation at positions 4-7-10-13-16. This advancement addresses earlier challenges with chemical synthesis that produced racemic mixtures with reduced biological activity.

The compound's metabolic profile reveals rapid conversion to bioactive metabolites upon oral administration. A pharmacokinetic study (Molecular Nutrition & Food Research 2024) showed peak plasma concentrations of resolvin D5 within 90 minutes post-ingestion. The half-life of approximately 8 hours supports once-daily dosing regimens for chronic therapeutic applications.

In food science applications, this methyl ester serves as a functional ingredient in nutraceutical formulations targeting cardiovascular health. Its incorporation into structured lipids has been shown to improve triglyceride clearance rates by modulating lipoprotein lipase activity without affecting essential fatty acid metabolism.

Ongoing research focuses on optimizing delivery systems through nanoencapsulation technologies to enhance bioavailability further. Lipid nanoparticles coated with phosphatidylcholine have demonstrated sustained release profiles over a 24-hour period while maintaining Z-isomer integrity under gastrointestinal conditions.

The environmental sustainability aspect of production processes has gained attention recently. Microbial fermentation using genetically engineered yeast strains offers a scalable alternative to traditional fish oil extraction methods while maintaining consistent stereoisomer purity at positions 4/7/10/13/16.

In conclusion, the compound represented by CAS No. 31930-67-3 stands out among omega-3 derivatives due to its unique stereochemistry and multifaceted biological activities. Continued research into its mechanistic pathways and formulation technologies promises expanded applications across pharmaceuticals and functional foods sectors.

• 112-63-0(Methyl linoleate)
• 108698-02-8((All-Z)-7,10,13,16,19-Docosapentaenoic Acid Methyl Ester)
• 16326-32-2(γ-Linolenic Acid methyl ester)
• 1120-25-8(METHYL PALMITOLEATE)
• 112-62-9(Methyl oleate)
• 1120-34-9(Erucic Acid Methyl Ester)
• 17673-62-0(9,12-Octadecadienoicacid (9Z,12Z)-, (9Z,12Z)-9,12-octadecadien-1-yl ester)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)